[Cancer of the prostate: estrogen therapy].
From 1941, estrogens are usually used in the treatment of prostatic carcinoma, wrongly in case of adjuvant hormonotherapy and exceedingly because of cardiovascular toxicity from over dosages. A recall of their mechanism of action and toxicity allows to argue about the palliative treatment and to look to their use for the locally advanced cancers in order to get a tumoral reduction before radiotherapy. A pilot study realised by the authors shows that this hormono-radiotherapic protocol is achievable.
D004967:Estrogens / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D009919:Orchiectomy; D010865:Pilot Projects; D010902:Pituitary Gland / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D013739:Testosterone / Q000097:blood*; D013927:Thrombosis / Q000209:etiology; D014280:Triglycerides / Q000097:blood
D004967:Estrogens; D014280:Triglycerides; D013739:Testosterone
Cancer de la prostate: l'estrogénothérapie.